Article Contents ::
- 1 The Brand Name ASGINASE IU Has Generic Salt :: L-Asparaginase
- 2 ASGINASE IU Is From Company Ranbaxy S.S. Priced :: Rs. 1596
- 3 ASGINASE IU have L-Asparaginase is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name ASGINASE IU Has Generic Salt :: L-Asparaginase
ASGINASE IU Is From Company Ranbaxy S.S. Priced :: Rs. 1596
ASGINASE IU have L-Asparaginase is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
|L-Asparaginase||V||Rs. 1596||1 VIAL|
|Brand Name||Company / Manufacturers||Strength||Unit||Price / 1 VIAL|
|ASGINASE IU||Ranbaxy S.S.||10000IU.||1 VIAL||Rs. 1596|
|Company Brand Name||Salt Combination||Main Medical Class||Sub Medical Class|
|From Ranbaxy S.S. :: ASGINASE IU||L-Asparaginase||#N/A||#N/A|
Indications for Drugs ::
Acute Lymphocytic Leukemia
Drug Dose ::
6,000 International Units/m2 intramuscularly (IM) or intravenously (IV) three times a week Reconstitute in volume appropriate for the intended route of administration: For IM administration, reconstitute in 2 mL For IV administration, reconstitute in 5 mL For IM administration, limit the volume at a single injection site to 2 mL; if greater than 2 mL, use multiple injection sites. For IV administration, give over ? 30 min through side arm of an infusion of Sodium Chloride Injection or Dextrose Injection 5% (D5W) . Use reconstituted Elspar within eight hours.
Serious allergic reactions to Elspar or other Escherichia coli-derived L-asparaginases Serious thrombosis with prior L-asparaginase therapy Pancreatitis with prior L-asparaginase therapy Serious hemorrhagic events with prior L-asparaginase therapy
Drug Precautions ::
Anaphylaxis and other serious allergic reactions can occur. Observe patients for one hour after administration. Discontinue Elspar in patients with serious allergic reactions. Serious thrombotic events, including sagittal sinus thrombosis, can occur. Discontinue Elspar in patients with serious thrombotic events. Pancreatitis, in some cases fulminant or fatal, can occur. Evaluate patients with abdominal pain for pancreatitis. Discontinue Elspar in patients with pancreatitis. Glucose intolerance, in some cases irreversible, can occur. Monitor serum glucose. Coagulopathy can occur. Perform appropriate monitoring. Hepatotoxicity including hepatic failure can occur. Perform appropriate monitoring. Posterior Reversible Encephalopathy Syndrome (PRES). Do not interchange Elspar with Erwinia asparaginase or pegylated E. coli asparaginase [polyethylene glycol (PEG) asparaginase].
Drug Side Effects ::
Most common adverse reactions are allergic reactions (including anaphylaxis), hyperglycemia, pancreatitis, central nervous system (CNS) thrombosis, coagulopathy, hyperbilirubinemia, and elevated transaminases
Pregnancy category ::
Drug Mode of Action ::
Asparaginase interferes with malignant cell growth by breaking down asparagine to aspartic acid and ammonia as leukemic cells are unable to synthesise asparagine and depends on exogenous source of asparagine for survival. It acts on the G1 phase of the cell cycle.
Drug Interactions ::
Activity of methotrexate may be reduced if L-asparaginase is given before hand. Potentially Fatal: IV admin of asparaginase may increase vincristine neurotoxicity.